Solid Biosciences jumps on early-stage data from gene therapy

Solid Biosciences

18/02/2025 15:51

** Shares of Solid Biosciences  SLDB.O  rises 51.9% to $6.12
    ** Co says its experimental gene therapy for a rare muscle
wasting disorder was well-tolerated in 6 participants dosed in
an early-stage study
    ** Duchenne muscular dystrophy (DMD) is caused by mutations
in the dystrophin gene, which interferes with the production of
proteins needed to form healthy muscles
    ** Says no serious adverse events were observed
    ** Also says that some patients showed significant
improvements in multiple muscle health biomarkers
    ** Separately, co's 35.7 mln stock offering priced at $4.03
each, which was the last closing price of its shares
    ** SLDB has fallen ~56% in the last 12 months

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))